Examples of 'laropiprant' in a sentence
Meaning of "laropiprant"
laropiprant (noun) - A pharmaceutical compound that was investigated for its potential use in treating cardiovascular diseases
Show more definitions
- A drug used in combination with niacin to reduce blood cholesterol.
How to use "laropiprant" in a sentence
Basic
Advanced
laropiprant
Laropiprant is not expected to inhibit the production of prostaglandins.
It is unknown whether laropiprant is excreted in human breast milk.
Laropiprant crosses the placenta in rats and rabbits.
Animal studies have shown excretion of laropiprant in milk.
Effects of laropiprant on other medicinal products.
The active substances are nicotinic acid and laropiprant.
Laropiprant was not mutagenic or clastogenic in a series of genetic toxicology studies.
Nicotinic acid was also authorised in combination with laropiprant.
Laropiprant has been shown to be effective in reducing flushing symptoms induced by nicotinic acid.
Age had no clinically meaningful effect on the pharmacokinetics of laropiprant.
There are no data from the use of laropiprant in pregnant women.
Gender had no clinically meaningful effect on the pharmacokinetics of laropiprant.
Adding laropiprant to nicotinic acid reduced the symptoms of flushing caused by nicotinic acid.
What Pelzont contains • The active substances are nicotinic acid and laropiprant.
Laropiprant and its acyl glucuronide conjugate are the major circulating components in human plasma.
See also
What Tredaptive contains • The active substances are nicotinic acid and laropiprant.
Laropiprant Effects of laropiprant on other medicinal products Midazolam.
What Trevaclyn contains • The active substances are nicotinic acid and laropiprant.
Laropiprant itself has no cholesterol lowering effect, but it reduces facial flushes induced by niacin.
There is no experience with doses of laropiprant above 900 mg in humans.
Laropiprant is a potent and selective antagonist of DP1.
Studies in animals have shown reproductive toxicity at high doses of laropiprant see section 5.3.
Laropiprant blocks the receptors to which PGD2 normally attaches.
Studies in animals have shown foetal developmental toxicity at high doses of laropiprant see section 5.3.
Laropiprant suppresses PGD2 mediated flushing associated with administration of nicotinic acid.
They received either 2 grams of extended-release niacin addition 40 milligrams of laropiprant or homologous placebos.
Flushing efficacy of laropiprant has not been established past 24 weeks.
Effects of other medicinal products on laropiprant CYP3A4 Inhibitor.
Multiple doses of laropiprant 40 mg did not affect the pharmacokinetics of midazolam, a sensitive CYP3A4 substrate.
Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients.
Therefore, laropiprant is not an inducer or inhibitor of CYP3A4.
Pelzont nicotinic acid laropiprant withdrawn at Week 21.
Trevaclyn nicotinic acid laropiprant withdrawn at Week 21.
Tredaptive nicotinic acid laropiprant withdrawn at Week 21.
